Identification, structures and ontogenies of SARS-CoV-2 antibodies

NIH Pandemic-Era Grants

Pandemic Era Grants

2022

↗ Live URL (may be dead)

Document text

Principal Investigator: Tongqing  Zhou
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2022
Award: $712,375
Funding agency: National Institute of Allergy and Infectious Diseases

The recent emergence of SARS-CoV-2 Omicron and its sub-variant evaded neutralization by antibodies elicited against the viral spike protein of early variants. Rapid development of molecular probes based on new variants of concern and identification of neutralizing monoclonal antibodies against the new variants or with broad neutralizing potency against SARS-CoV-2 variants and diverse beta-coronaviruses could be one approach to treat or prevent infection by new variants. To discover novel monoclonal antibodies from the convalescent samples, we utilized our established probes platform and successfully designed and rapidly purified SARS-CoV-2 spike-ectodomain probes based on new variant sequences. To respond to the challenge of SARS-CoV-2 Omicron, we have identified antibodies that maintained the ability to neutralize the Omicron variant, despite most of the previously discovered antibodies failed to neutralize. We solved cryo-EM structures of representative antibodies in complex with the Omicron B.1.1.529 spike to reveal the structural basis of neutralization. We also identified antibody combinations with synergy in neutralization. We also identified antibody from a mouse immunized with mRNA encoding the SARS-CoV-2 spike. Our study revealed that this new antibody bound to diverse beta-coronavirus spikes and neutralized SARS-CoV-2 variants, SARS-CoV, and related sarbecoviruses. High-resolution x-ray crystal structure indicated that this antibody recognize a conserved S2 helix, which was occluded in both pre- and post-fusion spike conformations. Structural and neutralization analyses indicated that this new antibody neutralizes by inhibiting fusion and post-viral attachment. Comparison with other recently identified antibodies that broadly neutralize beta-coronaviruses enabled us to define a stem-helical supersite that can be a promising target for vaccine design.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><ACE2><Antibodies><Antigenic Determinants><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Binding Determinants><Binding Sites><COVID-19 antibody><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19 virus><Clinical Treatment Moab><CoV-2><CoV2><Combining Site><Complex><Cryo-electron Microscopy><Cryoelectron Microscopy><Crystallization><Development><Electron Cryomicroscopy><Epitopes><Generalized Growth><Genetic Alteration><Genetic Change><Genetic defect><Goals><Growth><Immunize><Infection prevention><Messenger RNA><Mice><Mice Mammals><Molecular Configuration><Molecular Conformation><Molecular Probes><Molecular Stereochemistry><Monoclonal Antibodies><Murine><Mus><Mutation><Prevent infection><Process><Property><Proteins><Reactive Site><Receptor Protein><Resolution><Roentgen Rays><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 antibody><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 antibody><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Sarbecovirus><Serology><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Site><Specificity><Structure><Tissue Growth><Vaccine Design><Variant><Variation><Viral><Wuhan coronavirus><X-Radiation><X-Ray Radiation><X-ray><Xray><angiotensin converting enzyme 2><angiotensin converting enzyme II><antibody against COVID-19><antibody against SARS-CoV-2><antibody against SARS-CoV2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody to COVID-19><antibody to SARS-CoV-2><antibody to SARS-CoV2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><base><beta CoV><beta coronavirus><betaCoV><betacoronavirus><bio-informatics tool><bioinformatics tool><conformation><conformational state><coronavirus disease 2019 antibody><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease-19 virus><cryo-EM><cryoEM><design><designing><developmental><genome mutation><hCoV19><insight><mAbs><mRNA><nCoV2><neutralizing antibody><neutralizing mAb><neutralizing monoclonal antibodies><novel><ontogeny><receptor><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe acute respiratory syndrome-CoV><stem><synergism><variants of concern><β CoV><β coronavirus><βCoV>